AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03644706
Drug: ADV7103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
Trial: NCT03644706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules.
Trial: NCT04837235
Drug: Hemay005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05288504
Drug: AVTX-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 600 mg administered subcutaneously three times during the study.
Trial: NCT05288504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sourced as normal saline administered subcutaneously three times during the study.
Trial: NCT04607837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
Trial: NCT06721052
Drug: Postoperative analgesia management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We ordered 400 mg intravenous ibuprofen for the patients every 8 hours during the postoperative period. We planned to perform 100 mg tramadol as a rescue analgesic if the patient's NRS score was above 4. We observed the patients for 24 hours in the postoperative period.
Trial: NCT06785012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT04767802
Drug: PTG-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepcidin mimetic
Trial: NCT05677893
Drug: MBS-COV
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.
Trial: NCT06478225
Drug: BGT007H Cell Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention roughly goes through 3 phases (the day of cell infusion is defined as day 0, d0):~1. Apheresis and baseline period: Eligible subjects are enrolled for leukapheresis to prepare BGT007H cell injection solution, and baseline assessment is performed from after apheresis to before preconditioning.~2. Preconditioning (d-5\~d-3): Patients begin preconditioning (FC regimen) 5 days before BGT007H cell administration. A 2-day rest and observation period is conducted after preconditioning.~   The FC regimen is as follows:~  * Fludarabine: 25\~30mg/m2/d, intravenous infusion, once a day, for 3 consecutive days;~  * Cyclophosphamide: 250\~350mg/m2/d, intravenous infusion, once a day, for 3 consecutive days.~3. Cell infusion (d0) and DLT observation period (d0\~d28).
Trial: NCT06363877
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of normal saline allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the solution, wash-out with 2L of normal saline, followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL normal saline solution, suctioned, then washed-out with 500 mL normal saline.
Trial: NCT06052267
Drug: TEV-56248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.
Trial: NCT05600036
Drug: ESK-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05600036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05594563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice a day
Trial: NCT05475769
Drug: Clinical evaluation
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive treatments under the criteria of the responsible physician and the response to these treatments will be prospectively collected.
Trial: NCT05004805
Drug: Saline nasal spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
Trial: NCT04873297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 ml of plain water Via NG
Trial: NCT06006832
Drug: Steroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintaining low-dose oral steroids
Trial: NCT05557253
Drug: Balanced Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
Trial: NCT05005338
Drug: BIIB122 (DNL151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses
Trial: NCT06031441
Drug: RO7566802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7566802 solution for infusion will be administered as specified in each treatment arm.
Trial: NCT05544539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
Trial: NCT05879991
Drug: BI 1810631 (C-14) formulation 1
RxNorm normalized name: TRIOLEIN, 1-C-14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1810631 (C-14) formulation 1
Trial: NCT06707090
Drug: TR987 0.1% gel + Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
Trial: NCT04743453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
Trial: NCT05076955
Drug: vancomycin-tobramycin-itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
Trial: NCT06331533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl was injected into the placebo side
Trial: NCT05039801
Drug: Glutaminase-1 Inhibitor IACS-6274
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06083922
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 1, 8 and 15, Cycles 1-8
Trial: NCT06161805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 hour infusion with saline (NaCl 0.9%)
Trial: NCT06041178
Drug: 2.5% flurbiprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)
Trial: NCT06041178
Drug: 98% aloe vera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)
Trial: NCT05740969
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cream
Trial: NCT05740969
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cream
Trial: NCT04258488
Drug: Vitamin K antagonist(warfarin)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For 12months, keep the international normalized ratio (INR) 1.7-3.0
Trial: NCT05769153
Drug: Sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Needleless syringe used to simulate an intravitreal injection
Trial: NCT06226025
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants randomized to this intervention will take 1 oral pill (0.5 milligrams (mg)) daily. They will attend 4 weekly behavioral sleep intervention sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
Trial: NCT05662215
Drug: Placebo for CK-3828136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for CK-3828136
Trial: NCT05400226
Drug: VGT-309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
Trial: NCT06646211
Drug: Methotrexate , Thiotepa and Zanubrutinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 5 - 10 Drug: Methotrexate~* Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12 hours after the infusion of methotrexate (MTX) ends, administered every 6 hours until the MTX plasma concentration is ≤ 0.1 μmol·L-¹ at 48 hours; plasma concentration monitoring time points: 0, 6, 24, 48, 72 hours.】 Other Names: MTX Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 5 for up to 10 cycle Drug: Zanubrutinib Zanubrutinib will be given at a dose of 160mg，bid，d1-d21
Trial: NCT06561256
Drug: Janus Kinase Inhibitor
RxNorm normalized name: Janus kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Janus Kinase Inhibitor in combination with corticosteroids
Trial: NCT06195540
Drug: Low Heparin Molecular Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician.
Trial: NCT05719285
Drug: Multi-Dose Antibiotic
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses
Trial: NCT05532618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of sodium chloride 0.9%
Trial: NCT04662723
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To reduce the progression of renal damage in IgAN Patients
Trial: NCT05205005
Drug: Endocalyx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,712mg (six capsules) of DSGP for eight weeks.
Trial: NCT05205005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
Trial: NCT05652504
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the study product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe. Normal saline will be used as a placebo, rather than a comparator vaccine being used, as currently there are no licensed vaccines available as IV formulations. The NS to be used in this trial will be an FDA-licensed product which is commercially available (sodium chloride for injection 10 mL by Pfizer). NS will be purchased by Sanaria and supplied to the clinical site.
Trial: NCT05264649
Drug: Guizhi-Shaoyao-Zhimu decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients consumed GZSD (4g paper bagged medicine) three times per day (total daily dose was 12 g/day) continuously during the 6-week intervention period.
Trial: NCT05969119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
Trial: NCT05132088
Drug: placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
Trial: NCT06223269
Drug: Skin Xenotransplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area.
Trial: NCT00000811
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04137978
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
Trial: NCT05899621
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT05899621
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT06516965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06127407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided as tablets, taken orally once daily.
Trial: NCT06220604
Drug: JNJ-77242113 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 matching placebo will be administered orally.
Trial: NCT05789056
Drug: QRX003, 4% Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Trial: NCT05999513
Drug: casdatifan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT06200168
Drug: Standard antiemetic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
Trial: NCT06200168
Drug: Standard antiemetic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
Trial: NCT05223868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet will be administered orally.
Trial: NCT05814367
Drug: Blink® Tears eye drops in a multidose bottle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT06204614
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be placed in reservoir 1 of the implantable microdevice.
Trial: NCT06204614
Drug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
Trial: NCT06204614
Drug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
Trial: NCT05249634
Drug: Jatenzo Pill
RxNorm normalized name: Jatenzo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet daily
Trial: NCT01048983
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
Trial: NCT06411210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo.
Trial: NCT05483010
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin is commercially available.
Trial: NCT05520775
Drug: Sham/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham subcutaneous injection
Trial: NCT04544189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg by mouth once daily, in a 28-day cycle
Trial: NCT05116865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match
Trial: NCT05657132
Drug: Meta paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
Trial: NCT06293625
Drug: Folfox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folfox chemotherapy (folinic acid, fluorouracil and oxaliplatin) for 6 weeks (3 courses) before surgery.
Trial: NCT05106153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally as per assigned treatment sequence.
Trial: NCT04911543
Drug: [18F]-JNJ-70099731
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]JNJ-70099731 injection will be administered intravenously.
Trial: NCT06414759
Drug: IV Loop Diuretics
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.
Trial: NCT05513950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of a physiological solution as placebo.
Trial: NCT05350774
Drug: IV immunoglobulin
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
Trial: NCT06137118
Drug: AZD0486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product administered via intravenous infusion.
Trial: NCT04868981
Drug: Matching Placebos for GST-HG141 tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses